NCI-2024-03452

A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects with Advanced Solid Tumors with MAPK Pathway Mutations

This Phase 1 research study aims to evaluate the safety, tolerability, pharmacokinetics, and recommended Phase 2 dose of D3S-002 monotherapy in adults with advanced solid tumors harboring mutations in the MAPK pathway. Advanced Solid Tumors with MAPK Pathway Mutations are cancers where mutations in the MAPK pathway have been identified. The MAPK pathway is involved in cell growth and proliferation, and mutations can lead to uncontrolled cell growth, a hallmark of cancer. D3S-002 likely targets specific abnormalities in the MAPK pathway, aiming to inhibit cancer cell growth driven by these mutations.

mutations: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05886920

Clinical Trial Site: Sinai

To see all available clinical trials click here.